Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 23, 2008
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibilityJeroen J Lammerts van Bueren, Wim K Bleeker, Annika Brännström, et al.
Mabs|August 4, 2020
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignanciesMitchell Evers, Toine Ten Broeke, J H Marco Jansen, et al.
Cancer Research|July 3, 2008
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodiesMichael Dechant, Wencke Weisner, Sven Berger, et al.
Bone Marrow Transplantation|July 11, 2021
Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMTFrédéric Baron, Maud Ngoya, Myriam Labopin, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Frontiers in Immunology|February 23, 2026
Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assaysMiriam Kelm, Nourhan Nasr, Sonja Bendig, et al.
Blood Advances|September 15, 2021
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Molecular Cancer Therapeutics|March 3, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR AntibodiesJoseph Tintelnot, Natalie Baum, Christoph Schultheiß, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Cancer Research|January 25, 2024
Human Tumor-Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal TrogocytosisSunil Singhal, Abhishek S Rao, Jason Stadanlick, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|April 23, 2008
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibilityJeroen J Lammerts van Bueren, Wim K Bleeker, Annika Brännström, et al.
Mabs|August 4, 2020
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignanciesMitchell Evers, Toine Ten Broeke, J H Marco Jansen, et al.
Cancer Research|July 3, 2008
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodiesMichael Dechant, Wencke Weisner, Sven Berger, et al.
Bone Marrow Transplantation|July 11, 2021
Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMTFrédéric Baron, Maud Ngoya, Myriam Labopin, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Frontiers in Immunology|February 23, 2026
Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assaysMiriam Kelm, Nourhan Nasr, Sonja Bendig, et al.
Blood Advances|September 15, 2021
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Molecular Cancer Therapeutics|March 3, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR AntibodiesJoseph Tintelnot, Natalie Baum, Christoph Schultheiß, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Cancer Research|January 25, 2024
Human Tumor-Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal TrogocytosisSunil Singhal, Abhishek S Rao, Jason Stadanlick, et al.
Pageof 11